• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

European Commission Grants Additional Indication to Merck’s Ervebo


Ebola Zaire vaccine now includes children aged one and older.

Worker of center for disease control describing effects of ebola virus mutation. Image Credit: Adobe Stock Images/motortion

Image Credit: Adobe Stock Images/motortion

Merck has confirmed that the European Commission (EC) has approved an expanded indication for Ervebo, its vaccine against Ebola caused by Zaire ebolavirus. Now cleared for use in children ages one and older, the treatment was previously approved for patients 18 and older in the European Union.

“Ebola virus disease is severe and potentially life-threatening for both children and adults. The European Commission’s expanded approval of ERVEBO for children 1 year of age and older is an important milestone for the prevention of disease caused by Zaire ebolavirus,” said Eliav Barr, MD, SVP, head of global clinical development, chief medical officer, Merck Research Laboratories, in a company press release. “When outbreaks of Ebola virus disease occur, they can quickly become a public health crisis. We are proud to play a role, alongside the global public health community, in helping to prepare for potential outbreaks of Zaire ebolavirus.”

Reference: European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older. Merck. September 7, 2023. Accessed September 7, 2023. https://www.merck.com/news/european-commission-expands-mercks-ervebo-ebola-zaire-vaccine-rvsv%ce%b4g-zebov-gp-live-indication-to-include-children-1-year-of-age-and-older/

Related Videos
Related Content